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Summary: Previous investigations performed in human diabetics demonstrate an increase in their urinary fibronec-
tin excretion which was already present in subjects without microalbuminuria and which was elevated prior to
functional restrictions. The present study was performed to examine whether in an experimental model these data
obtained in men can be confirmed using an animal experimental model, and to further study pathomechanisms of
diabetic nephropathy in rats. Fibronectin levels in serum and urine, and renal functional properties such as creatinine
clearance, urinary albumin and protein excretion were studied in rats rendered diabetic with streptozotocin and
compared with values of control and insulin treated animals for 5 months. Diabetic animals demonstrated the same
creatinine clearance, but slightly decreased albumin and total protein excretion rates compared to controls and
insulin "treated", euglycaemic animals. Diabetic rats showed a significantly increased excretion following day 42
compared to controls and insulin "treated" group. Concerning serum fibronectin, there was no significant difference
between control, diabetic and insulin "treated" animals. The urinary fragment pattern of fibronectin was analyzed
qualitatively by immunoblotting pattern and consisted of two main bands (Mr 66000 and 45 000). These bands were
not altered in controls, insulin "treated" and diabetic rats, independent of the stage of renal involvement in diabetes.
Present data provide evidence that fibronectin excretion is elevated in diabetic animals prior to functional restric-
tions, confirming results obtained in human diabetics. Therefore, determination of urinary fibronectin can serve as
a more sensitive indicator for renal involvement in diabetes mellitus than microalbuminuria or changes in glomerular
filtration rate. Urinary fibronectin excretion may therefore serve as an early marker for the renal involvement in
diabetes before the onset of clinical symptoms.
Introduction
Microalbuminuria is currently the first sign that may in-
dicate an incipient diabetic nephropathy. However, be-
fore microalbuminuria can be diagnosed, morphological
alterations in the kidney, such as basement membrane
thickening and mesangial expansion, occur (2, 5, 6),
which can not be determined by non-invasive methods.
In the kidneys of diabetics in comparison to the kidneys
of healthy volunteers, increased amounts of fibronectin,
a major component of the mesangial matrix of the glo-
meruli (7), are found by immunochemistry (8, 9).
Recently, Jackie-Meyer et al. (10) reported an increased
urinary fibronectin excretion in diabetic humans that was
already present in subjects without microalbuminuria and
was elevated prior to functional restrictions. Following
this investigation, the authors hypothesize that urinary fi-
bronectin excretion probably reflects the mesangial ex-
pansion due to the accumulation of extracellular matrix
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proteins caused by increased glucose concentration in the
tissue. Their observations raise the question whether the
excretion of urinary fibronectin might be one possibility
to examine early stages of diabetes induced kidney im-
pairment with non-invasive methods.
The present investigation was designed to examine
whether, in an experimental model, data obtained in dia-
betic humans can be confirmed in an animal model, and
to further study the mechanisms leading to elevated fibro-
nectin excretion in urine. Because of striking similarities
with respect to early alterations of basement membrane
metabolism in diabetic humans and in diabetic rats (11),
rats were used as an animal model for studying basement
membrane and mesangial cell metabolism in diabetes.
Additionally, the present study was performed to investi-
gate whether an elevated urinary fibronectin excretion is
accompanied by alterations of the pattern of the break-
down products of fibronectin found in urine.
Materials and Methods
Animals, sampling procedure and induction of diabetes
Eighteen male Wistar Kryptorch rats (Zentrales Tierlabor, Medi-
zinische Hochschule Hannover, Germany), weighing 251 ± 21 g
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at the beginning of the study, were divided at random into three
groups with six animals per group. In two groups diabetes was
induced by the administration of a single intravenous injection
of streptozotocin (50 mg/kg body weight in 0.1 mol/1 citrate
buffer, pH 4.5; Sigma, St. Louis, Mo,-USA). Starting one week
after the induction of diabetes, one group of the diabetic animals
received a daily subcutaneous injection of about 6 IE insulin
(MC-lnsulin Novo Lente, Novo Pharmaceuticals, Copenhagen,
Denmark), the other group had no further treatment. The animals
of the control group received only one injection of 0.1 mol/1
citrate buffer.
During the whole observation period, animals had free access to
rat chow (Altromin, Lage, Germany) and water ad libitum. Urine
samples were collected over a 12-hour night period in metabolic
cages just before and 7, 14, 28, 49, 63, 90, 118 and 147 days
after the induction of diabetes and the injection of citrate buffer,
respectively. Coinciding with the urine samples, blood samples
were taken from the retro-orbital plexus. All samples were supple-
mented with 10 ml/1 of 0.1 mol/1 phenyl-methyl-sulphonyl-fluoride
to inhibit protease activities.
Renal funct ion measurements
Endogenous creatinine clearance was determined by measuring se-
rum and urine creatinine with an automated creatinine analyzer
(Model R2, Beckman Instruments, GmbH, Munich, Germany).
Glucose was measured enzymatically with a commercially avail-
able test kit (Boehringer, Mannheim, Germany). Total urinary pro-
tein was analyzed according to Bradford (13) and urinary albumin
by rocket-immunoelectrophoresis (14).
Determinat ion of f ibronectin
Fibronectin in serum and urine was determined quantitatively by a
sandwich-enzyme-linked-immunosorbent-assay (15). The anti-fi-
bronectin antibodies were purchased from Dako AS (Copenhagen,
Denmark) and purified plasma fibronectin from Sigma Chemicals
(St. Louis, MO, USA). Alkaline phosphatase was conjugated to the
antibodies as described by Avrameas (16). Serum samples were
diluted 10000 fold and urine samples had to be neutralized with
solid tiis-hydroxymethyl-amino-methane.
Urinary fibronectin was analyzed qualitatively by protein blotting
as described elsewhere in detail (17). Briefly, urinary proteins were
separated electrophoretically using a linear 5-16% sodium dode-
cyl-sulphate-polyacrylamide gradient gel and transferred onto nit-
rocellulose by semidry-blotting (Sartoblot-11-S, Sartorius, Goet-
tingen, Germany) in a discontinuous buffer system (18). Fibronec-
tin was specifically detected by incubating the nitrocellulose suc-
cessively with anti-fibronectin antibodies raised in rabbits and anti-
rabbit-IgG antibodies coupled to alkaline phosphatase, both
purchased from Dako AS (Copenhagen, Denmark). Fibronectin
was stained by the alkaline phosphatase reaction as described by
Blake et al. (19).
Statistical analysis
The results are expressed as medians and ranges. The data obtained
within a group during the course of the experiments were analyzed
by the Wilcoxon test for paired samples. The data of the three ex-
perimental groups were compared with the Mann-Whitney test for
independent samples. The level of significance was defined as
α < 0.05.
Results
Glucose concentrat ion
The development of diabetes was evaluated by measur-
ing the serum concentrations of glucose after the induc-
tion of diabetes and by comparing the values with those
of controls and insulin treated animals. The serum glu-
cose concentrations for the three groups of animals are
shown in table 1. As demonstrated by significant in-
creases in serum glucose concentrations, diabetes was
fully established 21 days after streptozotocin injection
and hyperglycaemia stayed evident for the rest of the
study period. The hyperglycaemic group had a mean
blood glucose concentration of 25.9—32.0 mmol/1 21
days following streptozotocin injection, which was sig-
nificantly elevated (p < 0.05) over controls and diabetic
euglycaemics. Following injection of insulin the serum
glucose concentration decreased to hypoglycaemic val-
ues of 2.2 (1.7-5.5) mmol/1 on day 77. Control animals
did not show appreciable changes in serum glucose con-
centration during the study period. On day 21 and day
104, insulin treated animals showed marked hypergly-
caemia in comparison to controls.
Creatinine clearance
The creatinine clearance for the three study groups of
animals is summarized in table 2. In general, creatinine
clearance of diabetic rats was in the same range as creat-
inine clearance of control and insulin treated, euglycae-
mic animals. Median values ranged from 3.07 to 5.28
Tab. 1 Glucose in serum of diabetic rats, insulin treated rats and
controls (mmol/1; medians and ranges)
Days
0
21
28
42
63
77
104
132
161
Controls
7.0 (3.9-9.7)
9.0 (8.6-9.7)
7.3 (5.9-8.0)
7.6(6.3-7.9)
6.7 (5.6-8.7)
7.2 (5.9-7.3)
6.8(5.9-8.1)
6.1 (5.4-7.0)
6.9 (5.7-8.0)
Insulin treated
animals
7.7 (5.8- 8.3)
21.7(12.7-31.5)a-b
8.6 (4.6-18.9)c
4.3 (3.6-17.5)c
4.4 (2.0-15.7)°
2.2 (1.7- 5.5)
21.9(16.9-23.0)
15.4 (7.3-29.3)
8.4 (7.8-24.6)
Diabetic animals
7.0 (6.7- 7.6)
28.5 (25.9-32.0)a-b
28.6/25.6-29.8)a'b
29.1 (22.3-36.4)a>b
27.7 (24.5 -29.9)a-b
23.5 (19.9^25.0)a-b
31.9(30.7-39.2)a-b
33.6 (27.3 -40.6)a'b
28.3(24.1-30.5)a'b
a
 significance vs. value at day 0;
b
 significance vs. controls;
c
 significance vs. diabetic animals.
Tab. 2 Creatinine clearance of diabetic rats, insulin treated rats
and controls (ml/min X kg; medians and ranges)
Days Controls
0 6.06(4.98-6.81)
21 5.05(4.25-6.76)
28 6.06 (5.24-6.65)
42 4.43 (3.77-4.91)
63 6.26(5.33-6.91)
77 5.74(4.47-7.21)
104 6.30(5.01-7.07)
132 6.98(6.12-8.97)
161 6.43(5.03-9.64)
Insulin treated Diabetic animals
animals
6.68(5.75-7.21)° 5.28(3.95-5.84)
7.12 (6.95-8.73)b-° 4.16 (1.52-4.98)
2.46 (1.56-3.29)a-b 3.26 (1. 67-4.3 l)a-b
7.86(6.13-8.13)b«c 4.51 (2.46-5.36)
6.84 (5.47-8.17)° 3.92 (2.96-5.68)b
6.30 (5.85-6.99) 3.28 (1.52-5.83)
6.42 (5.98-8.04) 5.37 (2.76-7.67)
3.40 (3.11-4.16) 5.57 (2.67-7.47)
4.30 (3.90-7.70) 3.07 (2.22-4.20)
a
 significance vs. value at day 0;
b
 significance vs. controls;
° significance vs. diabetic animals.
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ml/min X kg. However, at days 28,63 and 161 following
steptozotocin injection, creatinine clearance of diabetic
animals was significantly decreased compared to control
animals. Creatinine clearance was constant during the
rest of the study period. Insulin treated animals demon-
strated a significantly increased value at days 21 and 42,
but decreased value at day 28 in comparison to control
animals.
Urinary protein excretion
Total urinary protein excretion is shown in figure 1.
There were significant decreases in urinary protein
excretion, from 7.9 to 1.5 mg/12 h, following the induc-
tion of diabetes in comparison to control animals. There
was no significant difference between controls and eug-
lycaemic animals.
Urinary albumin excretion
Urinary albumin excretion for the various groups is
summarized in figure 2. In all six diabetic rats, albumin
excretion decreased statistically significantly during 42
days from 0.5 to 0.1 mg/12 h following streptozotocin
injection in comparison to controls and insulin treated
rats. In all six diabetic rats however, the relative contri-
bution of albumin to total urinary protein increased (data
not shown). Albumin excretion of euglycaemic, insulin
treated animals did not increase significantly during the
whole study period and was in the same range as values
of control animals. At the end of the study period the
average albumin excretion of control rats was 1.1 (0.9-
2.1) mg/12 h and did not differ significantly from the
value in the beginning of the study period.
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Fig. l Urinary protein excretion in diabetic animals (c), insulin treated animals (b) and controls (a).
Horizontal bars represent the medians of the entire group, α < 0.05
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Fig. 2 Urinary albumin excretion in diabetic animals (c), insulin treated animals (b) and controls (a).
Horizontal bars represent the medians of the entire group, α < 0.05
Serum fibronectin
Fibronectin levels were determined in serum of diabetic
animals, insulin treated animals and control animals.
These 3 groups showed no differences in serum fibro-
nectin level concentrations during the whole observation
period (tab. 3).
Urinary fibronectin excretion
The urinary excretion of fibronectin for all three groups
is shown in figure 3. The determination of urinary fibro-
nectin showed an increased excretion in all diabetic rats
following day 42, from 117 to 703 ng/12 h compared to
the control group and insulin treated group. The values
differed markedly between different diabetic animals.
Some diabetic rats excreted increased amounts of fibro-
nectin much earlier. Fibronectin was elevated in urine
of diabetic rats even when albumin excretion was not
Tab. 3 Fibronectin in serum of diabetic rats, insulin treated rats
and controls (mg/1; medians and ranges)
Days
0
21
28
42
63
77
104
132
161
Controls
220(131/300)
158(109/196)
184(112/124)
265(184/286)
384 (307/583)
250(133/388)
316(143/327)
122(112/288)
362(245/581)
Insulin treated
animals
163 (102/275)
224(163/306)
305(169/408)
180(102/286)
352(214/418)
296 (244/306)
Diabetic animals
200(153/414)
131 (120/164)
153(112/203)
235 (94/286)
361 (296/424)
203 (153/203)
180(112/225)
138(112/186)
347 (255/469)
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Fig. 3 Urinary excretion of fibronectin in diabetic animals (c), insulin treated animals (b) and controls (a).
Horizontal bars represent the medians of the entire group, α < 0.05
elevated. In controls, no changes in fibronectin excretion
could be observed. Values of medians ranged from 117
to 191 ng/12h. The excretion of fibronectin in insulin
treated rats did not differ significantly from the excre-
tion in control rats. In contrast to diabetic animals, fibro-
nectin excretion of insulin treated animals did not
increase.
Qualitative evaluation
A representative immunoblot is shown in figure 4. It
was demonstrated that fibronectin was excreted in a dis-
tinct, recurrent fragment pattern consisting of two main
protein bands with an apparent relative molecular mass
of Μτ 66 000 and 45 000. The urinary fragment pattern
of fibronectin was similar in all 3 animal groups and did
not alter during the whole study period, independent of
the stage of renal involvement in diabetes.
Discussion
To search for significant pathogenetic mechanisms in the
renal disease of insulin-deficient diabetes, research has
recently been focused on early events. The present study
was designed to compare pathomechanisms of nephro-
pathy in humaris with those in rats and to further study
mechanisms leading to elevated fibronectin excretion
in urine.
Because of striking similarities with respect to the alter-
ations of basement membrane metabolism in diabetic
humans and in diabetic rats (11), rats served as an exper-
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Fig. 4 Representative immunoblot of the urinary fragment pattern
of fibronectin of control, diabetic and insulin treated animals. Two
bands in the range of MT 45 000 and 65 000 were present in all sam-
ples.
lane 1: control rat at day 0
lane 2: control rat at day 63
lane 3: diabetic rat at day 63
lane 4: insulin treated rat at day 63
lane 5: control rat at day 161
lane 6: diabetic rat at day 161
lane 7: insulin treated rat at day 161
imental animal model. Most of the morphological alter-
ations observed in untreated diabetic rats — especially
early changes — are observed as well in humans (11).
Rats, though, do not develop diabetic sclerosis, as de-
scribed by Kimmelstiel (23).
Glucose concentration was measured to prove whether
animals were diabetic and whether insulin treatment had
effects. Steptozotocin-treated animals exhibited elevated
blood glucose levels over the two other groups, the insu-
lin treated animals and control animals demonstrating
that diabetes was fully established 21 days after strepto-
zotocin injection and was successful over the whole
study period.
Diabetic animals had no increased creatinine clearance
compared to the two other study groups. This observa-
tion suggests that an early stage of renal impairment
could not be observed. Regarding total protein excretion,
diabetic rats and insulin treated rats did not develop pro-
teinuria during the first weeks of the study period. An
explanation in the present study could be the diabetic
acidosis leading to degrading of proteins. We could not
confirm studies made by other authors (25, 26, 27) who
demonstrated that, just as in type I diabetic patients, dia-
betic rats show a higher rate of creatinine clearance and
excretion of urinary protein. Treatment of the rats by
insulin led to rapid normalization of the functional alter-
ations (28). These authors state that the structural and
functional alterations in rat kidneys detected immedi-
ately after induction of diabetes are very similar to those
observed in patients during the first stage of diabetic
nephropathy (11). These observations apply irrespective
of the methods used for inducing diabetes (alloxan,
streptozotocin) (11).
The extent of renal involvement in diabetic rats was
specified by total protein excretion and by urinary albu-
min excretion, since microalbuminuria is currently the
most sensitive marker in humans and predictive for the
development of diabetic nephropathy (22). Control rats
as well as insulin treated rats did not demonstrate an
increased albumin excretion, indicating that the process
of glomerular injury had not begun. Also urinary albu-
min excretion in diabetic rats suggests that an early stage
of renal impairment could not be observed. In general,
diabetic animals showed individual differences in albu-
min excretion. In some cases extremely increased levels
of albumin excretion could be demonstrated.
This effect cannot be explained by aging alone, but also
by a diabetes induced kidney impairment. Although
microalbuminuria in diabetic rats has not been described
yet, it can be concluded that rats are quite useful for
studying early and intermediate stages of diabetic ne-
phropathy because of similar morphological changes.
Rats investigated in the present study show an early
stage of nephropathy without striking functional
changes.
In the present study, fibronectin concentration in serum
was not increased in diabetic animals in comparison to
insulin treated and control rats during the whole study
period. Studies performed by other authors showed in-
consistent results regarding human diabetics. Labat-
Roberi et al. (29) found a decreased plasma fibronectin
level in diabetics, whereas DeGiorgio et al. (30) reported
increased levels in patients with retinopathy and micro-
albuminuria. Davis et al. (31) could not find any differ-
ence in serum fibronectin content in diabetic and non-
diabetic persons. Regarding serum fibronectin levels in
rats, only a few studies have been made by other au-
thors. The increased concentration of serum fibronectin
described in diabetic humans is probably not present in
rats (32, 33).
There was a difference in urinary fibronectin excretion
between euglycaemic and hyperglycaemic diabetic ani-
mals, despite the fact that these groups did not exhibit
differences in renal function. Fibronectin was elevated
in urine of diabetic rats even when albumin excretion
was not elevated, whereas fibronectin excretion in insu-
lin treated rats was not elevated during the whole study
period and was not different from the fibronectin excre-
tion in control rats. These results provide evidence that
fibronectin excretion is elevated in diabetic animals
prior to functional restrictions. Therefore, our data ob-
tained in rats demonstrate that fibronectin can be modu-
lated by insulin treatment and give evidence for renal
involvement in diabetes mellitus. Because treatment
with insulin prevented increase in fibronectin excretion,
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this indicates that urinary fibronectin level is a conse-
quence of the diabetic state. According to the results in
diabetic rats, the euglycaemia found in insulin treated
rats has been shown to result in decreased fibronectin
excretion. Studies of Jackie-Meyer- et al. (10) obtained
in humans could be confirmed by studies in rats, demon-
strating that increased urinary fibronectin excretion in
diabetics was already present in subjects without micro-
albuminuria.
Furthermore, the reported effects in insulin treated ani-
mals can be explained by the hypothesis of some authors
who have described changes in uracil ribonucleotide
metabolism that can be prevented by insulin administra-
tion in the renal cortex of the streptozotocin-induced di-
abetic rat (34). In the present study, increased excretion
of urinary fibronectin excretion could be demonstrated
after induction of experimental diabetes and following
increased serum glucose levels. A possible explanation
comes from studies performed by Kreisberg et al. (35),
who show that fibronectin is elevated in response to high
glucose. Results presented by these authors by quantita-
tive RT-PCR showed that high glucose resulted in a
rapid, transient increase in c-fos mRNA followed by a
sustained increase in c-jun and fibronectin mRNA in
mesangial cell cultures.
Since the urinary excretion of fibronectin seems to be
valuable in assessing the early involvement of the kid-
ney in diabetes, the fibronectin excretion was studied not
only quantitatively but also qualitatively by immu-
noblotting. The aim was to investigate whether the ele-
vated urinary excretion of fibronectin is accompanied by
alterations of the pattern of the breakdown products of fi-
bronectin found in urine. The protein was excreted in a
distinct fragment pattern of two main bands with an ap-
parent relative molecular mass of A/r 66 000 and 45 000 in
the urine of control and of diabetic animals, independent
of the stage of renal involvement in diabetes.
According to Gwinner et al. (17), urinary fibronectin
fragments derive from the glomerulus under non-pro-
teinuric conditions. Because none of the rats in the pre-
sent study developed proteinuria, the unaltered and re-
curring fragment pattern is indicative that these frag-
ments are products of a defined turnover of fibronectin
in the kidney.
In summary, it was shown that urinary fibronectin excre-
tion is elevated in diabetic rats prior to functional restric-
tions. It probably reflects the mesangial expansion due
to the accumulation of extracellular matrix proteins, like
fibronectin, caused by increased glucose levels in the
tissue. With regard to these findings, urinary fibronectin
excretion may serve as an early marker for the renal
involvement in diabetes. This demonstrates the existence
of a very early quantitative but not qualitative change in
urinary fibronectin excreted in diabetic rats. Further-
more, it could be demonstrated in the present study that
rats provide a useful animal model for further studying
the underlying mechanisms leading to increased fibro-
nectin excretion in diabetes mellitus.
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